Corporate ActionJul 2, 2026, 08:33 AM
Cingulate Added to Russell 3000E® Index
AI Summary
Cingulate Inc. announced its inclusion in the Russell 3000E® Index, a significant achievement that is expected to enhance its visibility with institutional investors and expand market awareness. CEO Shane J. Schaffer highlighted that this inclusion further positions the company for long-term growth. Cingulate remains committed to advancing its lead ADHD product candidate, CTx-1301, and developing its proprietary Precision Timed Release™ (PTR™) platform.
Key Highlights
- Cingulate Inc. has been added to the Russell 3000E® Index.
- The inclusion is expected to enhance visibility with institutional investors and expand market awareness.
- CEO Shane J. Schaffer stated this positions the company for long-term growth.
- Cingulate is advancing CTx-1301, its lead ADHD product candidate.
- The company continues to develop its Precision Timed Release™ (PTR™) drug delivery platform.
- Russell US Indexes are reconstituted annually in June to accurately reflect market segments.
Price Impact
More from CING